$2.08
+0.00 (+0.00%)
Open$2.08
Previous Close$2.08
Day High$2.14
Day Low$2.08
52W High$33.65
52W Low$17.16
Volume—
Avg Volume327.7K
Market Cap5.04M
P/E Ratio29.71
EPS$1.00
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+1,656.3% upside
Current
$2.08
$2.08
Target
$36.53
$36.53
$23.38
$36.53 avg
$47.42
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 996.2K | 899.1K | 945.5K |
| Net Income | -293,752 | -268,437 | -236,795 |
| Profit Margin | -29.5% | -29.9% | -25.1% |
| EBITDA | -415,155 | -429,552 | -415,366 |
| Free Cash Flow | -272,222 | -251,567 | -250,593 |
| Rev Growth | -1.0% | -1.1% | +22.5% |
| Debt/Equity | 0.30 | 0.28 | 0.27 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |